A securities class action lawsuit has been filed against ImmunityBio, Inc. (NASDAQ: IBRX) as it is accused of fraudulent behavior by failing to disclose crucial information to investors. The lawsuit aims to cover those who bought ImmunityBio securities from January 19, 2026 to March 24, 2026. This legal action comes on the heels of revelations concerning undisclosed data impacting the company's share price.